Diagnosing rapidly and accurately is vitally important during a flu outbreak, however, until now, there was no method of doing so; therefore, healthcare professionals had decide whether to use a time-consuming method that is very accurate or a quick method that is not so. A new method of flu diagnosis is both rapid and accurate. [...]
A study conducted by researchers at the Emory Vaccine Center has revealed a method to predict whether a person will produce high levels of antibodies in response to a flu shot a few days after receiving it. The study results appeared online in the Nature Immunology journal on July 10. The researchers performed a scan [...]
With the help of sophisticated modeling and statistical analyses, David Fisman and his team demonstrate that infection with influenza is likely to increase the occurrence of invasive pneumococcal disease (IPD). There is a possibility this infection increases the short-term chances of bacterial invasion in people who are already colonized with Streptococcus pneumoniae (which causes IPD) by making the lining of the airways more permeable to the bacteria.
Twitter, the revolutionary social networking site that captured the minds and hearts of people—commoners, celebrities, politicians, and the like—has allowed for so many changes in communication. With over 140 characters worth of a statement, anyone can blab about anything under the sun: tsunami aftermaths, breakthrough dance singles, and annoying neighbors. Even businessmen are using Twitter as an effective marketing strategy.
iBio, Inc. has announced positive interim results from a Phase 1 clinical trial of an iBioLaunch™ platform-produced subunit vaccine for Influenza A/California/04/09 (H1N1). The vaccine showed strong induction of dosage correlated immune responses, whether adjuvant was used or not, as assessed by virus microneutralization antibody assays and hemagglutination inhibition (HAI) responses. Use of the vaccine was safe and the vaccine was well tolerated at all dosages when given with and without adjuvant.
The H1N1 disease once caused a global scare because of its debilitating complications. Since then, vaccines against the influenza virus were created to protect humankind. Recently, the Fraunhofer USA Center for Molecular Biotechnology (CMB) was able to develop a vaccine produced from plants. The researchers have announced the success of the first clinical trial of this vaccine to humans.